rhPRG4 reduced phagocytic activation of gout monocytes both under basal and primed conditions and this reduction resulted in a downstream attenuation of IL-1β secretion, and rhPRG4’s efficacy was equivalent to a clinically approved biologic, IL-1RA. Here, IL1B is linked to gout.